Tuesday, April 16, 2024

Pfizer Unveils Latest Findings at IDWeek 2023, Showcasing Progress in Preventing and Treating Specific Respiratory Ailments and Other Infectious Conditions

Similar articles

Pfizer will share data from its infectious disease research at IDWeek 2023 in Boston, happening from October 11 to 15, 2023. This data, consisting of 45 abstracts, will focus on Pfizer’s advancements in preventing and treating specific infectious diseases, particularly respiratory illnesses. Notably, Pfizer’s research includes assessing the public health impact of ABRYSVO™, its vaccine designed to protect infants from respiratory syncytial virus (RSV) illness through maternal immunization.

Annaliesa Anderson, Ph.D., Senior Vice President and Head of Vaccine Research and Development at Pfizer, emphasized Pfizer’s dedication to enhancing respiratory health and addressing global health challenges through its diverse pipeline of innovative vaccines and anti-infective treatment candidates.

Luis Jodar, Ph. D., Chief Medical Affairs Officer for Vaccines/Antivirals and Evidence Generation at Pfizer, stressed the significant burden of respiratory illnesses on global public health, especially as the Northern Hemisphere faces the potential co-circulation of influenza, RSV, and COVID-19 during the winter respiratory season. Pfizer aims to educate healthcare professionals at IDWeek about how its vaccines and treatments can help mitigate the impact of respiratory infections during this crucial period.

Pfizer’s participation at IDWeek 2023 encompasses groundbreaking research spanning RSV, COVID-19, pneumococcal disease, Lyme disease, meningococcal disease, multidrug-resistant gram-negative bacterial infections, and more. Notably, eight abstracts will be presented orally, featuring data on coadministering ABRYSVO with an influenza vaccine in older adults and results from the Phase 3 REVISIT study of Pfizer’s investigational antibiotic combination aztreonam-avibactam (ATM-AVI). The meeting will also highlight real-world data on Pfizer’s FDA-approved COVID-19 oral treatment for adults, PAXLOVID™.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article